Entera Bio Ltd. Ordinary Shares Stock Prediction
AI-powered sentiment analysis and prediction trends for ENTX, updated each market day.
ENTX AI Sentiment
AI sees no strong directional signal for Entera Bio Ltd. Ordinary Shares stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Entera Bio Ltd. Ordinary Shares
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Sector
Exchange
Market Cap
$524,619,747
Cap Tier
Employees
22
Headquarters
JERUSALEM
Listed Since
June 28, 2018
Website
ENTX Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ENTX Volatility
Entera Bio Ltd. Ordinary Shares has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
